ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Simple Search Results

Didn't find what you were looking for? Try the Advanced Search »

  • 1
  • 2
  • 3
  • …
  • 101
  • Next Page »
Search Again »
  • Abstract Number: 0129 • ACR Convergence 2024

    The Efficacy and Safety of Telitacicept Following Rituximab Immunotherapy on Antiphospholipid Syndrome, a Prospective 24- Week Study

    Qiang Shu1, Qing Zuraw2, Xiaoyu Zhang3, Guillermo Pons-Estel4, Shuning Sun5, Qincheng Che1, Xinyu Li6, Jie Li6 and Qi Liu6, 1Qilu Hospital, Shandong Provincial Clinical Research Center for Immune Disease and Gout, Jinan, China; Qilu Hospital, Cheeloo College of Medicine, Shandong University, Rheumatology, Jinan, China, Jinan, China (People's Republic), 2RemeGen Biosciences, Inc., South San Francisco, China (People's Republic), 3Qilu Hospital, Shandong Provincial Clinical Research Center for Immune Disease and Gout, Jinan China, Beijing, China, 4Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ROSARIO, Santa Fe, Argentina, 5Qilu Hospital, Shandong Provincial Clinical Research Center for Immune Disease and Gout, Jinan, China; Qilu Hospital, Cheeloo College of Medicine, Shandong University, Pheumatology, Jinan, China, Jinan, China (People's Republic), 6Qilu Hospital, Jinan, China (People's Republic)

    Background/Purpose: Antiphospholipid syndrome (APS) is a challenging disease to treat and lack effective therapies. Rituximab (RTX) can deplete CD20+ peripheral B cells. Telitacicept (TA) is…
  • Abstract Number: 0244 • ACR Convergence 2024

    Adjunctive Belimumab Exerts Favorable Ferritin Recovery and Survival for Post-COVID Interstitial Lung Disease in Patients with Immune Mediated Inflammatory Diseases Treated with Rituximab: A Case Series

    Pei-Hsinq Lai1, Cheng-Hsun Lu2 and Song-Chou Hsieh3, 1Taipei City Hospital, Taipei, Taiwan (Republic of China), 2National Taiwan University Hospital, Taipei, Taiwan, 3National Taiwan University Hospital, Taipei, Taiwan (Republic of China)

    Background/Purpose: Post-COVID interstitial lung disease (post-COVID ILD) is a critical sequelae yet the role of immunomodulatory therapies remains unclear. We explored to characterize post-COVID ILD…
  • Abstract Number: 0252 • ACR Convergence 2024

    Prospective Study of Severe Infectious Events and Immune Reconstitution After Rituximab in Autoimmune Diseases

    Aurélien Chepy1, Michaël Genin2, Louis Terriou3, Cécile Chenivesse4, Delphine Staumont-Sallé5, Hélène Zéphir6, Peggy philippe7, Guillaume Lefevre8, Sarah Stabler9, Eric HACHULLA3, David Launay10 and Vincent Sobanski3, 1Univ. Lille, Inserm, CHU Lille, U1286—INFINITE—Institute for Translational Research in Inflammation, Lille, France., Lille, Nord-Pas-de-Calais, France, 2Univ. Lille, CHU Lille, ULR 2694 - METRICS: Évaluation des technologies de santé et des pratiques médicales, Lille, F-59000, France., Lille, France, 3CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France., Lille, France, 4Centre de Référence Constitutif des Maladies Pulmonaires Rares, CHU Lille, Service de Pneumologie et Immuno-Allergologie, Lille 59000, France., Lille, France, 5Service de dermatologie CHU Lille Université de Lille Lille France., Lille, France, 6Department of Neurology, CRC-SEP, CHU of Lille, Lille, France., Lille, France, 7Rheumatology Department, Lille University Hospital, Lille, France., Lille, France, 8CHU Lille, Institut d’Immunologie, Lille, France., Lille, France, 9CHU Lille, Service Universitaire de Maladies Infectieuses, F-59000 Lille, France; Univ. Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France., Lille, France, 10CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France., Lille Cedex, France

    Background/Purpose: Rituximab (RTX) administration in autoimmune diseases (AID) is associated with severe infectious events (SIE). Frequency of SIE and immune reconstitution (B cells, T cells,…
  • Abstract Number: 0289 • ACR Convergence 2024

    Effectiveness of Rituximab in IgG4 Related Disease

    Fernando Lopez-Gutierrez1, Javier Loricera2, Cristina Hormigos3, Dalifer Freites Nuñez4, Maria Rodriguez-Laguna5, Patricia Moya Albarado6, Marta López I Gómez7, Hèctor Corominas8, Maite Silva-Díaz9, GUILLERMO GONZALEZ ARRIBAS9, Angel Garcia-Aparicio10, Judit Font Urgelles11, Ivette Casafont-Sole11, Pablo Martínez Calabuig12, Elisabet Castaneda13, Carolina Merino14, Raquel Zas15, Juan Molina-Collada16, Rafael Benito Melero-Gonzalez17, Eva Galindez-Agirregoikoa18, Andrea Hernández-Martín19, Lucia Pantoja20, Ignacio Brana Abascal21, Vega Jovani22, Elia Valls-Pascual23, Natalia Mena Vázquez24, Adela Gallego- Flores25, Noelia Cabaleiro Raña26, Raul Veroz27, Mariano Andres28, Santos Castañeda29 and Ricardo Blanco-Alonso30, and Rituximab in IgG4 Related Disease Spanish Cooperative Group, 1Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, 2Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 3Hospital Clínico San Carlos, Madrid, Madrid, Spain, 4Hospital Clínico San Carlos. Madrid. Spain., Madrid, Spain, 5Resident in Rheumatology, Madrid, Spain, 6Hospital de San Pau, Barcelona, Spain, 7Hospital Universitario Alava, Vitoria, Pais Vasco, Spain, 8Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 9Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, 10Hospital Universitario de Toledo, Toledo, Spain, 11Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 12HOSPITAL GENERAL UNIVERSITARIO VALENCIA SPAIN, Ontinyent, Comunidad Valenciana, Spain, 13Hospital Universitario Infanta Sofía, Madrid, Madrid, Spain, 14Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda (Madrid), Spain, 15Hospital Universitario 12 de Octubre, Madrid, Madrid, Spain, 16Hospital General Universitario Gregorio Marañón, Madrid, Spain, 17CHU Ourense, O Carballino, Spain, 18BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, 19Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas, Spain, 20Complejo Hospitalario Segovia, Segovia, Castilla y Leon, Spain, 21Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain, 22National Health system, Alicante, Spain, 23Hospital General de Valencia, Valencia, Comunidad Valenciana, Spain, 24IBIMA, Málaga, Andalucia, Spain, 25Hospital Perpetuo Socorro, Badajoz, Spain, 26Hospital Universitario Montecelo, Pontevedra, Galicia, Spain, 27Hospital de Merida, Merida, Extremadura, Spain, 28Hospital General Universitario de Alicante, Alicante, Spain, 29Hospital Universitario de la Princesa, Madrid, Spain, 30Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic fibroinflammatory disease often associated with elevated serum IgG4 levels. High dose corticosteroids are the cornerstone of treatment, but…
  • Abstract Number: 0338 • ACR Convergence 2024

    Anti-MDA5 Antibody-positive Dermatomyositis Associated Interstitial Lung Disease – Survival Benefit of Treatment with Rituximab, Janus Kinase Inhibitor and Glucocorticoid Combination in a Prospective Cohort

    Cheryl Chun Man Ng1, Kitty Yan Kwok1, Chup-Hei Ho1, Tze-Chung Ho1, Chu-Oi Ciang2 and Moon-Ho Leung1, 1Queen Elizabeth Hospital, Hong Kong, Hong Kong, 2QEH, Hong Kong., Hong Kong, China

    Background/Purpose: Anti-melanoma differentiation-associated protein 5 antibody associated dermatomyositis (Anti-MDA5 DM) is known to be an aggressive disease. Earlier cohorts reported a 1-year mortality of 38%-57%, with rapidly…
  • Abstract Number: 0513 • ACR Convergence 2024

    Effects of Cumulative Rituximab Exposure in Patients with Rheumatoid Arthritis: Results from Cohort at a Tertiary Academic Health Care Setting

    Ioasaf Karafotias1, Maryam Adas1, Katie Bechman1, Nicholas Williamson1, Mark Hughes1, Daksh Mehta2, Ritika Roy1, Sam Norton3 and James Galloway4, 1King's College London, London, United Kingdom, 2King's College Hospital, London, United Kingdom, 3King's College London, London, England, United Kingdom, 4Centre for Rheumatic Diseases, King's College London, London, United Kingdom

    Background/Purpose:  Rituximab targets CD20-positive B cells and is used to treat rheumatoid arthritis (RA). B cell depletion may result in hypogammaglobulinemia. Hypogammaglobulinemia is a risk…
  • Abstract Number: 0526 • ACR Convergence 2024

    Comparing Immunogenicity and Safety Following Transition from Reference Rituximab to Biosimilar Rituximab (DRL_RI) in Patients with Rheumatoid Arthritis: A Randomized, Double-blind, Phase 3 Study

    Narendra Maharaj1, Dharma rao Uppada2, Naveen Reddy MAREDDY1, Pramod Reddy Pundra1, Anastas Batalov3, Delina Ivanova4, nedyalka staykova5, Asta Baranauskaite6 and Laila Hassan7, 1Clinical Development - Biologics, Dr. Reddy’s Laboratories Ltd., Bachupally, Hyderabad 500090, India, Hyderabad, India, 2Clinical Development - Biologics, Dr. Reddy’s Laboratories Ltd., Bachupally, Hyderabad 500090, India, Hyderabad, 3Medical University of Plovdiv, Medical Faculty, University Hospital "Kaspela", Clinic of Rheumatology, Plovdiv 4000, Bulgaria, Plovdiv, Bulgaria, 4Diagnostic and Consulting Center Aleksandrovska EOOD Sofia 1431, Bulgaria, Sofia, Bulgaria, 5Outpatient Clinic for Specialized Medical Help – Medical Center Kuchuk Paris OOD; Plovdiv 4004, Bulgaria, plovdiv, Bulgaria, 6Hospital of Lithuanian University of Health Sciences Kauno Klinikos, LT-50161, Lithuania, Kaunas, Lithuania, 711914 Astoria Blvd. Ste. 330, Houston TX 77089 United States, Houston, TX

    Background/Purpose: To assess immunogenicity and safety in patients with active rheumatoid arthritis (RA) transitioning from US-Rituximab (RP) or EU-Rituximab (RMP) to DRL_RI (proposed rituximab biosimilar),…
  • Abstract Number: 0535 • ACR Convergence 2024

    Oral Glucocorticoid Premedication Is at Least as Effective as Intravenous Glucocorticoid Premedication for Prevention of Infusion-related Reactions to Rituximab in Rheumatoid Arthritis Patients

    Pauline Bovens1, Luuk Van Esveld2, Maike Wientjes1, Noortje van Herwaarden3, David Ten Cate4, Eward Melis3, Nienke Lesuis5, Bart van den Bemt6 and Alfons den Broeder1, 1Sint Maartenskliniek, Ubbergen, Netherlands, 2Sint Maartenskliniek, Utrecht, Netherlands, 3Sint Maartenskliniek, Nijmegen, Netherlands, 4Sint Maartenskliniek, Rotterdam, Netherlands, 5Hospital Group Twente, Almelo, Netherlands, 6Sint Maartenskliniek / Radboudumc, Ubbergen, Netherlands

    Background/Purpose: It has been demonstrated that pretreatment with intravenous glucocorticoids can prevent infusion-related reactions (IRR) that may occur in RA patients receiving rituximab infusions [1].…
  • Abstract Number: 0825 • ACR Convergence 2024

    Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator (BRAVO): 6-month Outcomes of a Longitudinal Cohort Study

    Arielle Mendel1, Lillian Barra2, Sasha Bernatsky3, Alison Clifford4, Mojtaba Dabaghjamanesh5, Natasha Dehghan6, Aurore Fifi-Mah7, Jean-Paul Makhzoum8, Rosalie-Sélène Meunier9, Nataliya Milman10, Medha Soowamber11, Jan Willem Cohen Tervaert12, Elaine Yacyshyn4, Nader Khalidi13 and Christian Pagnoux14, 1McGill University Health Centre, Montreal, QC, Canada, 2Western University, London, ON, Canada, 3Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 4University of Alberta, Edmonton, AB, Canada, 5Western University, Canada, Richmond Hill, ON, Canada, 6University of British Columbia - Vancouver, Vancouver, BC, Canada, 7University of Calgary, Calgary, AB, Canada, 8Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, 9Hôpital Sacré-Coeur, Université de Montréal, Montreal, QC, Canada, 10the Ottawa Hospital, Ottawa, ON, Canada, 11Mount Sinai Hospital, Woodbridge, ON, Canada, 12University of Alberta, Edmonton, Canada, 13McMaster University, Hamilton, ON, Canada, 14Mount Sinai Hospital, Toronto, ON, Canada

    Background/Purpose: To evaluate the effectiveness and safety of rituximab (RTX) biosimilars compared to the originator in Canadians with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis…
  • Abstract Number: 1162 • ACR Convergence 2024

    Evaluating the Efficacy of Rituximab in the Treatment of Refractory Adult Idiopathic Inflammatory Myositis Using Total Improvement Score: Data from a Real-World Multi-Centre Registry in the United Kingdom

    Xia Lyu1, Patrick Gordon2, Harsha Gunawardena3, Neil McHugh4, Sarah Tansley4, Athiveeraramapandian Prabu5, Peter Lanyon6, James Miller7, Voon Ong8, Anthony Isaacs9, Chee-Seng Yee10, Caroline Cotton11, Patrick Kiely12, Eleni Stathopoulou13, James Taylor14, Rachel Jeffery14, Anurag Bharadwaj15, James Lilleker16, Janine Lamb17 and hector Chinoy18, and MYOPROSP consortium, 1Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China (People's Republic), 2nhs, London, United Kingdom, 3North Bristol NHS Trust, and Academic Rheumatology, University of Bristol, Bath, United Kingdom, 4University of Bath, Bath, United Kingdom, 5Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom, 6Nottingham University Hospitals NHS Trust, and Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham, United Kingdom, 7Department of Neurology, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom, 8University College London, London, England, United Kingdom, 9Department of Rheumatology, London North West University Healthcare NHS Trust, London, United Kingdom, 10Department of Rheumatology, Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust, Doncaster, United Kingdom, 11Department of Rheumatology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom, 12Department of Rheumatology, St George's University Hospitals NHS Foundation Trust, London, United Kingdom, 13Department of Rheumatology, Solihull Hospital, University Hospitals of Birmingham NHS FT, Birmingham, United Kingdom, 14Department of Rheumatology, Northampton General Hospital, Northampton General Hospital NHS Trust, Northampton, United Kingdom, 151Basildon University Hospital, Mid & South Essex NHS Foundation Trust, Rheumatology, Basildon, United Kingdom, Basildon, United Kingdom, 16Northern Care Alliance NHS Trust, Salford, United Kingdom, 17University of Manchester, UK, Manchester, United Kingdom, 18The University of Manchester, Manchester, United Kingdom

    Background/Purpose: B cell depletion in the form of rituximab (RTX) is an established treatment modality for idiopathic inflammatory myopathies (IIM). Treatment response is now assessed…
  • Abstract Number: 1276 • ACR Convergence 2024

    Therapeutic Drug Monitoring (TDM) of Rituximab to Predict Early B-Cell Repopulation in Children

    Rana Alsulami1, Bindiya Chugani2, Joley Johnstone2, Ann Yeh2, Floris Loeff3, Linda Hiraki2, Andrea Knight4, Deborah Levy2 and Ruud Verstegen2, 1University of Toronto, Toronto, ON, Canada, 2The Hospital for Sick Children, Toronto, ON, Canada, 3Sanquin Diagnostic Services, Amsterdam, Netherlands, 4Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Rituximab is increasingly used in pediatric inflammatory diseases, with dosing extrapolated from adult data due to a lack of pediatric-specific pharmacokinetic (PK) information. Children…
  • Abstract Number: 1396 • ACR Convergence 2024

    Low CD47 Expression on B Cells, Induces High B Cell Phagocytosis by Macrophages and Is a Predictive Biomarker of Anti-rituximab Antibodies and Lower Response in Rheumatoid Arthritis

    Samuel Bitoun1, Bineta Ly2, Audrey Paoletti2, Catherine Menier Menier3, Marc Pallardy4, Bernard Maillere5 and Xavier Mariette6, and ABIRISK consortium, 1Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicetre, France, 2Rheumatology departement, Université Paris Saclay, Inserm UMR 1184,Hopital Bicêtre, APHP, FHU CARE, Le Kremlin Bicêtre, France, 31 CEA, INRAE, Département Médicaments et Technologies pour la Santé, SIMoS, Université de Paris-Saclay, Gif sur Yvette, France, 4Université Paris-Saclay, INSERM, Inflammation Microbiome Immunosurveillance, Orsay, France, 5CEA, INRAE, Département Médicaments et Technologies pour la Santé, SIMoS, Université de Paris-Saclay, Gif sur Yvette, France, 6Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France

    Background/Purpose: Rituximab (RTX) provides long lasting efficacy in the control of rheumatoid arthritis. Among factors associated with RTX failure are the occurrence of anti-drug antibodies…
  • Abstract Number: 1539 • ACR Convergence 2024

    Effectiveness & Safety of Early versus Late Use of Rituximab in Extra-renal Lupus: Real World Experience from a Tertiary Care Centre

    JOHN KUMAR DAS1, ABHILASHA ARVIND MANWATKAR2 and JOHN MATHEW2, 1Christian Medical College, Vellore, India, 2christian medical college, vellore, Tamil Nadu, India

    Background/Purpose: Rituximab, a monoclonal antibody targeting CD20 positive B cells failed to show effectiveness in SLE, including EXPLORER and LUNAR trials.However, real world data in…
  • Abstract Number: 1541 • ACR Convergence 2024

    Effect of Rituximab on Long-term Damage Acquisition in Patients with Systemic Lupus Erythematosus

    Amanda Brito1, Teresa Moitinho de Almeida2, Sofia Miranda3, Miriam Barreto Baié1, Daniel Calado3 and David Isenberg4, 1Instituto de Medicina Integral Professor Fernando Figueira, Recife, Brazil, 2Unidade Local de Saúde de Lisboa Ocidental, Lisboa, Portugal, 3Hospital do Divino Espírito Santo, Ponta Delgada, Portugal, 4University College London, London, United Kingdom

    Background/Purpose: B-cell depletion has been used to treat patients with systemic lupus erythematosus (SLE) for over twenty years, but we still lack studies that evaluate…
  • Abstract Number: 1727 • ACR Convergence 2024

    Duration of SARS-CoV-2 Viral Shedding After Infection Among Patients with Rheumatic Disease Using Tumor Necrosis Factor Inhibitors or Rituximab

    Zachary Wallace1, Li Yijia2, Manish Choudhary2, Julie Boucau3, Anusha Nathan3, May Yee Liew3, Gregory Edelstein2, Owen Glover3, Yumeko Kawano2, Rockib Uddin3, Rinki Deo2, Caitlin Marino3, Matthew Getz3, Zahra Reynolds4, karry Su4, Eliza Passell4, Mamadou Barry4, Rebecca Gilbert4, Dessie Tien4, Shruti Sagar4, Tammy Vyas4, Sarah Hammond2, Jatin Vyas4, Gaurav Gaiha4, Jacob Lemieux4, Mark Siedner4, Jonathan Li2, Amy Barczak4 and Jeffrey Sparks5, 1Massachusetts General Hospital, Newton, MA, 2Brigham and Women's Hospital, Boston, MA, 3Ragon Institute of MGH, Boston, MA, 4Massachusetts General Hospital, Boston, MA, 5Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA

    Background/Purpose: Individuals with rheumatic disease receiving certain immunosuppressive agents are at risk for severe COVID-19. However, it is unclear if rheumatic disease treatments affect the…
  • 1
  • 2
  • 3
  • …
  • 101
  • Next Page »
Search Again »

Didn't find what you were looking for? Try the Advanced Search »

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology